ÂÜÀòÂÒÂ×

Jennifer Locke has extensive experience in operational and business leadership within the biotechnology sector, holding positions such as Chief Operating and Business Officer at multiple Morningside Portfolio Companies, including Adiso Therapeutics, ClearB Therapeutics, and Artugen Therapeutics from 2019 to December 2023. Prior to these roles, Jennifer served as Senior Director and Director of Project Management at Seres Therapeutics and as Senior Program Manager at both Merck and Cubist Pharmaceuticals. Jennifer's educational background includes an Executive Leadership for Women certificate from Cornell University, a Master of Science in Project Management and Global Business from Boston University, and a Bachelor's degree in English, Spanish, and Women's Studies from Fairfield University.